San Diego's Cytori Therapeutics' board of directors has appointed Ruud J.P. Jona to serve as a director of the company, and the company has nominated Gail K. Naughton, Ph.D. to serve as an independent director on the board of directors.
Jona was appointed pursuant to the stock purchase agreement, dated Oct. 29, 2013, between the company and Lorem Vascular, in which the company granted Lorem Vascular the right to appoint one designated individual to serve on the board.
Cytori entered into a strategic relationship with Lorem Vascular, a company founded by Australian businessman K.T. Lim with the purpose of commercializing Cytori Cell Therapy in China and parts of Asia, in October 2013. Lorem Vascular will be initially focused on the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia.
Jona served on the board of various Riverside-owned companies and served as CEO of Philips Central Europe, as CEO of Philips Malaysia and held other management and sales and marketing roles at the company. Jona has served on the Board of a number of companies including Vokes Air Holding AB, Teufel GMBH and Think Appliances Pty Ltd.
He holds a bachelor's degree in business administration from the European University of Antwerp in Belgium and an M.B.A. from the University of Dallas.
Naughton was the co-founder and co-inventor of the technology at Advanced Tissue Sciences where she held key management positions for more than 15 years, including president, chief operating officer and director. She also served as the dean of the College of Business Administration at San Diego State University for nine years. Currently, Naughton serves as the CEO and the chairman of the board of Histogen, a regenerative medicine company she founded in 2007. Naughton also currently serves on the board of directors for CR Bard Inc.
Naughton holds a B.S. in biology from St. Francis College, as well as a master's in histology and a Ph.D. from New York University Medical Center. She also holds an E.M.B.A. from the Anderson School at the University of California, Los Angeles. If accepted, the appointment will become effective July 1.